H. Hurwitz

发表

Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.

F. Kabbinavar, H. Hurwitz, J. Yi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, The New England journal of medicine.

A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303

Yusuke Nakamura, Chen Jiang, Kouros Owzar, 2011, Clinical Cancer Research.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

F. Kabbinavar, H. Hurwitz, L. Fehrenbacher, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor.

Bruce Klitzman, Mark W Dewhirst, James M Grichnik, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.

A. Secord, H. Hurwitz, A. Nixon, 2014, Gynecologic oncology.

The search for biomarkerstodirect antiangiogenic treatmentin epithelial ovarian cancer

A. Secord, H. Hurwitz, A. Nixon, 2014 .

Staging of pancreatic cancer before and after neoadjuvant chemoradiation

E. Paulson, H. Hurwitz, D. Tyler, 2001, Journal of Gastrointestinal Surgery.

Phase I studies

A. Muehler, K. Venkatakrishnan, J. Nemunaitis, 2010 .

Understanding and targeting resistance to anti-angiogenic therapies.

H. Hurwitz, J. Clarke, 2013, Journal of gastrointestinal oncology.

Prenylation of CaaX-type proteins: Basic principles through clinical applications

P. Casey, H. Hurwitz, 2002 .

Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study

H. Hurwitz, J. Yi, N. Moore, 2011, British Journal of Cancer.

Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.

H. Hurwitz, Shermini Saini, 2006, Seminars in oncology.

Preoperative Chemoradiation for Patients With Locally Advanced Adenocarcinoma of the Pancreas

M. Anscher, H. Hurwitz, D. Tyler, 1999, Annals of Surgical Oncology.

Phase I Trial of Pazopanib in Patients with Advanced Cancer

E. Merkle, H. Hurwitz, A. Dowlati, 2009, Clinical Cancer Research.

Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage.

M. Byrne, H. Hurwitz, D. Tyler, 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004 .

Bevacizumab Combined with Standard Fluoropyrimidine-Based Chemotherapy Regimens to Treat Colorectal Cancer

F. Kabbinavar, H. Hurwitz, 2005, Oncology.

Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy

David H. Johnson, F. Kabbinavar, H. Hurwitz, 2005 .

Clinical evaluation of nitric oxide responses to anti-VEGF therapy with bevacizumab

Jason D. Allen, H. Hurwitz, J. Bendell, 2007 .

Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.

H. Hurwitz, J. Bendell, M. Morse, 2008, Journal of the American College of Surgeons.

Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC)

H. Hurwitz, J. Bendell, G. Blobe, 2008 .

Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.

J. Tabernero, F. Kabbinavar, H. Hurwitz, 2013, The oncologist.

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.

H. Hurwitz, D. Rischin, M. Rosenthal, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer

T. J. Mcmanus, G. Hobbs, A. Armstrong, 2014, Cancer Chemotherapy and Pharmacology.

A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.

C. Willett, H. Hurwitz, D. Cohen, 2008, International journal of radiation oncology, biology, physics.

A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.

Daohai Yu, C. Willett, D. Harpole, 2007, International journal of radiation oncology, biology, physics.

Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.

C. Willett, R. Clough, H. Hurwitz, 2007, International journal of radiation oncology, biology, physics.

Phase I study of pazopanib plus TH-302 in advanced solid tumors

H. Hurwitz, R. Riedel, D. Niedzwiecki, 2017, Cancer Chemotherapy and Pharmacology.

A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.

H. Hurwitz, J. Bendell, G. Blobe, 2011, Clinical colorectal cancer.

Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer

H. Hurwitz, S. Yaung, J. Bendell, 2022, Cancers.

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk

F. Kabbinavar, H. Hurwitz, A. Zurlo, 2008, Oncology.

Monoclonal Antibodies to EGFR: What Does the Future Hold?

H. Hurwitz, Y. Zafar, 2007 .

Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.

Daohai Yu, C. Willett, H. Hurwitz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2012, The oncologist.

Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer Does Not Influence Survival

M. Anscher, H. Hurwitz, D. Tyler, 2001, Annals of Surgical Oncology.

Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

Anti-VEGF therapies in the clinic.

H. Hurwitz, K. Meadows, 2012, Cold Spring Harbor perspectives in medicine.

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors

H. Hurwitz, W. Petros, R. Cohen, 2006, Cancer Chemotherapy and Pharmacology.

New combinations in metastatic colorectal cancer: what are our expectations?

H. Hurwitz, 2005, The oncologist.

Phase I I, R andomized T rial C omparing B evacizumab P lus Fluorouracil ( FU)/Leucovorin ( LV) W ith F U/LV A lone i n Patients W ith M etastatic C olorectal C ancer

F. Kabbinavar, H. Hurwitz, L. Fehrenbacher, 2003 .

A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.

M. Anscher, H. Hurwitz, D. Tyler, 2004, International journal of radiation oncology, biology, physics.

Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2014, Pharmacoepidemiology and drug safety.

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors

H. Hurwitz, J. Bendell, H. Pang, 2014, Investigational New Drugs.

Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.

E. Van Cutsem, G. Lyman, H. Hurwitz, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer?

H. Hurwitz, H. Uronis, 2007, Nature Clinical Practice Oncology.

Circulating D‐dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma

M. Dewhirst, K. Blackwell, H. Hurwitz, 2004, Cancer.

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer

H. Lenz, A. Grothey, H. Hurwitz, 2018, British Journal of Cancer.

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer

H. Hurwitz, M. Carducci, R. Pili, 2014, Investigational New Drugs.

Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.

H. Hurwitz, J. Clarke, F. Rangwala, 2014, Cancer treatment reviews.

Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study

H. Hurwitz, D. Niedzwiecki, Christel N. Rushing, 2015, Supportive Care in Cancer.

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

S. McCall, H. Hurwitz, G. Blobe, 2014, Investigational New Drugs.

Ziv-aflibercept: binding to more than VEGF-A--does more matter?

H. Hurwitz, J. Clarke, 2013, Nature reviews. Clinical oncology.

A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

H. Hurwitz, E. Mitchell, T. Cartwright, 2012, The oncologist.

Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2010 .

Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.

C. Willett, R. Clough, H. Hurwitz, 2009, International journal of radiation oncology, biology, physics.

Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability.

H. Hurwitz, J. Strickler, 2012, The oncologist.

A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)

H. Hurwitz, J. Bendell, G. Blobe, 2011, Cancer Chemotherapy and Pharmacology.

Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.

T. Gruenberger, H. Hurwitz, J. Bendell, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)

H. Hurwitz, D. Niedzwiecki, G. Blobe, 2019, Cancer Chemotherapy and Pharmacology.

A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.

A. Armstrong, H. Hurwitz, D. George, 2014, Clinical genitourinary cancer.

Benefit from bevacizumab (BV) is independent of pretreatment plasma vascular endothelial growth factor-A (pl-VEGF) in patients (pts) with metastatic colorectal cancer (mCRC)

H. Hurwitz, E. Holmgren, E. Ryan, 2005 .

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

L. Lipton, H. Hurwitz, L. Rosen, 2013, BMC Cancer.

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules

R. Advani, H. Wakelee, H. Hurwitz, 2010, Clinical Cancer Research.

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

David C. Smith, H. Hurwitz, H. Pitot, 2015, Cancer Chemotherapy and Pharmacology.

Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.

H. Hurwitz, J. Clarke, A. Nixon, 2015, Cancer journal.

Targeted inhibition of VEGF receptor 2: an update on ramucirumab

H. Hurwitz, J. Clarke, 2013, Expert opinion on biological therapy.

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors

C. Castañeda, H. Hurwitz, S. Kaufmann, 2011, Cancer Chemotherapy and Pharmacology.

Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004 .

Clinical benefit from bevacizumab (BV) in responding (R) and non-responding (NR) patients (pts) with metastatic colorectal cancer (mCRC)

H. Hurwitz, S. Sarkar, S. Holden, 2005 .

Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.

H. Hurwitz, D. Niedzwiecki, G. Blobe, 2021, The oncologist.

Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas

E. Paulson, M. Anscher, H. Hurwitz, 2001, Annals of Surgical Oncology.

First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results.

David C. Smith, H. Hurwitz, H. Pitot, 2014 .

Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): Preliminary results.

H. Hurwitz, Z. Wainberg, H. Burris, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.

G. Wilding, H. Hurwitz, D. Cohen, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents.

E. Perez, J. Hainsworth, C. Swanton, 2015 .

Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma.

D. Marin, Rajan T. Gupta, H. Hurwitz, 2017, Radiology.

Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004 .

Lack of effect of bevacizumab on wound healing/bleeding complications when given 28-60 days following primary cancer surgery.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Title The effect of different dosing regimens of motesanib on the gallbladder : a randomized phase 1 b study in patients with advanced solid tumors Permalink

L. Lipton, H. Hurwitz, L. Rosen, 2013 .

Immunotherapy with Autologous, Human Dendritic Cells Transfected with Carcinoembryonic Antigen mRNA

E. Gilboa, H. Hurwitz, J. Schlom, 2003, Cancer investigation.

A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.

H. Hurwitz, R. Riedel, H. Pang, 2018, The oncologist.

Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database.

C. Bokemeyer, E. Van Cutsem, R. Goldberg, 2022, European journal of cancer.

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer

H. Hurwitz, H. Pang, C. Theuer, 2014, Cancer medicine.

Dual inhibition of &agr;V integrins and Src kinase activity as a combination therapy strategy for colorectal cancer

H. Hurwitz, A. Nixon, I. Cushman, 2013, Anti-cancer drugs.

Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors

H. Hurwitz, A. Dowlati, D. Collins, 2005 .

Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: an updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study

J. Hainsworth, R. Bose, C. Swanton, 2019 .

An intervention to improve cancer patients' understanding of early-phase clinical trials.

S. Goodman, H. Hurwitz, M. Carducci, 2009, IRB.

Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC)

H. Hurwitz, D. Goldstein, H. Burris, 2007 .

A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors

H. Hurwitz, J. Bendell, D. Niedzwiecki, 2019, Cancer Chemotherapy and Pharmacology.

Significance of Histological Response to Preoperative Chemoradiotherapy for Pancreatic Cancer

E. Paulson, H. Hurwitz, D. Tyler, 2005, Annals of Surgical Oncology.

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.

H. Hurwitz, C. Sweeney, E. Chiorean, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Daniel J Sargent, Christophe Tournigand, Eduardo Diaz-Rubio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC).

H. Hurwitz, J. Bendell, G. Blobe, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effectiveness and safety of second-line (2L) irinotecan- and oxaliplatin-based regimens after first-line (1L) bevacizumab (BV)-containing treatment (tx) for metastatic colorectal cancer (mCRC): Results from the ARIES observational cohort study.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.

H. Hurwitz, G. Blobe, M. Morse, 2010, Anticancer research.

FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials.

T. Gruenberger, H. Hurwitz, J. Bendell, 2020 .

Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).

G. Sledge, P. Douglas, H. Hurwitz, 2010 .

Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience.

C. Willett, R. Clough, H. Hurwitz, 2003, International journal of radiation oncology, biology, physics.

Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.

J. Hainsworth, R. Bose, C. Swanton, 2017 .

Carcinoma of the Ampulla of Vater: Patterns of Failure Following Resection and Benefit of Chemoradiotherapy

C. Willett, H. Hurwitz, D. Tyler, 2012, Annals of Surgical Oncology.

A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.

H. Hurwitz, J. Bendell, G. Blobe, 2013, The oncologist.

Reply to S. Hapani et al

G. Lyman, H. Hurwitz, U. Rohr, 2011 .

Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.

J. Hainsworth, R. Bose, C. Swanton, 2017 .

Sunitinib for patients (pts) with advanced imatinib (IM)-refractory GIST: Early results from a "treatment-use" trial.

G. Demetri, H. Hurwitz, C. Baum, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.

R. Burger, M. Birrer, A. Secord, 2016 .

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

J. Berlin, H. Lenz, J. Marshall, 2018, British Journal of Cancer.

Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.

G. Rosner, A. Bass, H. Hurwitz, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

J. Baselga, I. Chirivella, J. Tabernero, 2010, Clinical Cancer Research.

Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors.

H. Hurwitz, A. Dowlati, A. Suttle, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer

J. Marshall, H. Hurwitz, N. Rizvi, 2004, Clinical Cancer Research.

Can Pha Act

I. Chirivella, J. Tabernero, P. Elvin, 2010 .

Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).

J. Albanell, J. Tabernero, H. Hurwitz, 2017 .

Abstract 2651: Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma

P. Hegde, H. Hurwitz, J. Bendell, 2016 .

Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors

H. Hurwitz, E. Chan, B. Nelson, 2007 .

Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.

O. Margalit, W. Harmsen, H. Lenz, 2022, European journal of cancer.

Primary tumor location as a prognostic factor in metastatic colorectal cancer.

H. Lenz, H. Hurwitz, L. Saltz, 2015, Journal of the National Cancer Institute.

Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis.

F. Kabbinavar, H. Hurwitz, S. Sarkar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.

J. Christensen, G. Shapiro, H. Hurwitz, 2015 .

Metastatic ampullary adenocarcinoma presenting as a hydrocele: a case report.

D. Blazer, R. Bentley, T. Polascik, 2014, JOP : Journal of the pancreas.

Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors.

Daohai Yu, H. Hurwitz, J. Bendell, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials.

F. Marshall, E. Jaffee, J. Simons, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway.

J. Hainsworth, R. Bose, C. Swanton, 2017 .

Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303.

M. Bertagnolli, P. Friedman, R. Goldberg, 2011, Journal of Clinical Oncology.

A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer.

H. Hurwitz, J. Bendell, G. Blobe, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

403PPhase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC)

J. Albanell, J. Tabernero, H. Hurwitz, 2017 .

Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC).

A. Grothey, H. Hurwitz, S. Sarkar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265-101).

G. Shapiro, H. Hurwitz, C. Maroun, 2009, Journal of Clinical Oncology.

A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer

Daohai Yu, H. Hurwitz, G. Blobe, 2005 .

STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

J. Reeves, H. Hurwitz, J. Bendell, 2014 .

Introduction: Targeting Angiogenesis in Cancer Therapy

H. Hurwitz, 2004 .

A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently.

J. Verweij, H. Hurwitz, A. Suttle, 2006, Journal of Clinical Oncology.

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.

Suzanne F. Jones, M. Ellis, A. Stead, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

J. Nemunaitis, H. Hurwitz, Z. Wainberg, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.

A. Jubb, G. Frantz, K. Hillan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Study of Eniluracil/5-FU in Combination with Radiation Therapy for Potentially Resectable and/or Unresectable Cancer of the Pancreas and Distal Biliary Tract

Daohai Yu, H. Hurwitz, D. Tyler, 2006, Cancer investigation.

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

J. Hainsworth, R. Bose, C. Swanton, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.

O. Chinot, D. Miles, H. Hurwitz, 2020, Cancer treatment reviews.

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

M. Ellis, A. Stead, K. Blackwell, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of molecular biomarkers to inform adjuvant therapy for colon cancer.

H. Hurwitz, D. Hsu, N. Mettu, 2013, Oncology.

Genetic variants in the platelet‐derived growth factor subunit B gene associated with pancreatic cancer risk

K. Owzar, Hongliang Liu, Q. Wei, 2018, International journal of cancer.

Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway.

J. Hainsworth, R. Bose, C. Swanton, 2017 .

A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer

A. Armstrong, H. Hurwitz, D. George, 2008, Clinical Cancer Research.

Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?

H. Hurwitz, J. Strickler, 2013, Current Oncology Reports.

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors

H. Hurwitz, R. Riedel, J. Bendell, 2012, Cancer Chemotherapy and Pharmacology.

Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

H. Hurwitz, M. Morse, W. Petros, 2009, Anticancer research.

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.

A. Jubb, K. Hillan, F. Kabbinavar, 2005, Journal of the National Cancer Institute.

Development of a Novel c-MET–Based CTC Detection Platform

M. Garcia-Blanco, M. Harrison, A. Armstrong, 2016, Molecular Cancer Research.

Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

R. Burger, K. Owzar, M. Birrer, 2020, Clinical Cancer Research.

Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)

M. Bertagnolli, P. Friedman, R. Goldberg, 2013, Clinical Cancer Research.

Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).

Ivo D. Shterev, P. Febbo, E. Small, 2013 .

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

H. Hurwitz, H. Pang, Yingmiao Liu, 2013, Cancer medicine.

Predictive Biomarkers and Personalized Medicine Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer : Results from CALGB 80303 ( Alliance )

M. Bertagnolli, P. Friedman, R. Goldberg, 2013 .

Neoadjuvant Chemoradiation for Rectal Cancer: Analysis of Clinical Outcomes From a 13-Year Institutional Experience

M. Anscher, H. Hurwitz, H. Seigler, 2001, Annals of surgery.

Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)

Ivo D. Shterev, K. Owzar, H. Hurwitz, 2014, Clinical Cancer Research.

Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing

H. Hurwitz, H. Pang, Eric S. Weiss, 2015, Clinical Cancer Research.

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.

J. Hainsworth, R. Bose, C. Swanton, 2019, The Lancet. Oncology.

Phase Ib/II study of pembrolizumab with lanreotide depot for advanced, progressive gastroenteropancreatic neuroendocrine tumors (PLANET).

H. Hurwitz, D. Hsu, D. Niedzwiecki, 2021 .

Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.

E. Perez, J. Hainsworth, R. Bose, 2016 .

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

David S Mendelson, Michael K Wong, H. Hurwitz, 2012, Clinical Cancer Research.

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

R. Schilsky, R. Goldberg, H. Hurwitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.

G. Sledge, P. Douglas, H. Hurwitz, 2013, The oncologist.

Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.

H. Hurwitz, 2004, Clinical colorectal cancer.

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer

A. Bardelli, F. Penault-Llorca, S. McCall, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors

H. Hurwitz, P. Marcom, M. Morse, 2012, Cancer Chemotherapy and Pharmacology.

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

M. Hidalgo, E. Van Cutsem, H. Hurwitz, 2018, Investigational New Drugs.

Angiogenesis pathway inhibitors.

R. Herbst, H. Hurwitz, T. Isobe, 2005, Cancer chemotherapy and biological response modifiers.

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.

F. Kabbinavar, H. Hurwitz, Jiuzhou Wang, 2007, Journal of the National Cancer Institute.

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

J. Berlin, J. Hainsworth, F. Kabbinavar, 2005, Journal of surgical oncology.

VEGF Inhibition for Cancer Therapy

H. Hurwitz, Shermini Saini, 2008 .

Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.

H. Hurwitz, N. Fernando, 2003, Seminars in oncology.

D. Cella, F. Kabbinavar, H. Hurwitz, 2008, The oncologist.

Quality of life (QoL) impact of bevacizumab (BV) when combined with irinotecan + 5-FU/leucovorin (IFL) and 5-FU/leucovorin (FL) for metastatic colorectal cancer (mCRC)

D. Cella, H. Hurwitz, B. Nelson, 2005 .

Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors

J. Verweij, H. Hurwitz, P. Hamberg, 2013, Investigational new drugs.

Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.

H. Hurwitz, J. Strickler, 2012, The oncologist.

Companion Diagnostics and Cancer Biomarkers Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus

H. Hurwitz, H. Pang, Yingmiao Liu, 2022 .

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib

G. Demetri, H. Hurwitz, Yoon-Koo Kang, 2015, Cancer.

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

David Goldstein, Serge Leyvraz, Patrick Schöffski, 2012, Clinical Cancer Research.

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.

H. Lenz, J. Marshall, H. Hurwitz, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

C. Tournigand, D. Sargent, M. Buyse, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.

H. Hurwitz, J. Yi, O. Rosen, 2009, The oncologist.

Purpose and Benefits of Early Phase Cancer Trials: What Do Oncologists Say? What Do Patients Hear?

S. Goodman, H. Hurwitz, M. Carducci, 2008, Journal of empirical research on human research ethics : JERHRE.

A leave-one-out cross-validation SAS macro for the identification of markers associated with survival

Anuradha Bulusu, Herbert Pang, Christel Rushing, 2015, Comput. Biol. Medicine.

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer

H. Lenz, H. Hurwitz, M. Fakih, 2022, JAMA network open.

Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

C. Tournigand, M. Buyse, C. Bokemeyer, 2019, JAMA network open.

An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)

Y. Furukawa, K. Owzar, M. Ratain, 2019, Pharmacogenetics and genomics.

A phase I study of ABT-510 plus bevacizumab in advanced solid tumors

H. Hurwitz, J. Bendell, G. Blobe, 2013, Cancer medicine.

Combinations of Bevacizumab With Cancer Immunotherapy

H. Hurwitz, Daniel S. Chen, 2018, Cancer journal.

Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.

H. Hurwitz, T. S. Collins, Timothy S. Collins, 2005, Seminars in oncology.

Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?

K. Weinfurt, D. Sulmasy, Li Lin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 1 First-in-Human Study of TRC 105 ( Anti-Endoglin Antibody ) in Patients with Advanced Cancer

H. Hurwitz, W. Figg, L. Rosen, 2012 .

Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

H. Hurwitz, R. Griffiths, T. Coffman, 2009, Hypertension.

Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study

R. Larson, H. Hurwitz, K. Rai, 2002, Cancer Chemotherapy and Pharmacology.

The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.

H. Hurwitz, H. Awad, B. Klitzman, 2005, The Journal of surgical research.

Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.

H. Hurwitz, C. Ock, J. Clarke, 2018 .

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.

F. Kabbinavar, H. Hurwitz, S. Sarkar, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA.

R. Nelson, E. Paulson, H. Hurwitz, 2003, Gastrointestinal endoscopy.

Everolimus in colorectal cancer

H. Hurwitz, I. Altomare, 2013, Expert opinion on pharmacotherapy.

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

H. Hurwitz, N. Spector, Rakesh Kumar, 2008, Cancer Immunology, Immunotherapy.

Targeted therapy of colorectal cancer: clinical experience with bevacizumab.

H. Hurwitz, N. Fernando, 2004, The oncologist.

Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.

John Thomas, Daohai Yu, C. Willett, 2007, International journal of radiation oncology, biology, physics.

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.

E. Van Cutsem, N. Harbeck, D. Miles, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer

H. Hurwitz, S. Yaung, J. Bendell, 2020, Clinical Cancer Research.

Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer

H. Hurwitz, H. Lyerly, M. Morse, 2013, Current Colorectal Cancer Reports.

Partner‐assisted emotional disclosure for patients with gastrointestinal cancer

Hong-Jin Kim, H. Hurwitz, D. Baucom, 2009, Cancer.

The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer

E. Gilboa, H. Hurwitz, J. Schlom, 2002, International journal of gastrointestinal cancer.

A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.

H. Hurwitz, J. Bendell, G. Blobe, 2011, The oncologist.

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer

Suzanne F. Jones, N. Agarwal, H. Hurwitz, 2013, Clinical Cancer Research.

Clinical summary of 67 heavily pre-treated patients with metastatic carcinomas treated with GW572016 in a phase Ib study.

A. Stead, D. Smith, H. Hurwitz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Highlights in metastatic colorectal cancer from the American Society of Clinical Oncology Annual Meeting, June 3-7, 2011, Chicago, Illinois.

H. Hurwitz, 2011, Clinical advances in hematology & oncology : H&O.

The social context of gastrointestinal cancer pain: a preliminary study examining the relation of patient pain catastrophizing to patient perceptions of social support and caregiver stress and negative responses

E. Clipp, H. Hurwitz, I. Lipkus, 2003, PAIN®.

Phase I study of ACE-041, a novel inhibitor of ALK1-mediated angiogenesis, in patients with advanced solid tumors.

H. Hurwitz, J. Bendell, M. Gordon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic variation determines VEGF-A plasma levels in cancer patients

Ivo D. Shterev, R. Gordân, Y. Furukawa, 2018, Scientific Reports.

Metastatic Colorectal Cancer for Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin Health-Related Quality of Life Impact of Bevacizumab When Combined with

D. Cella, F. Kabbinavar, H. Hurwitz, 2013 .

Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors

D. Potvin, H. Hurwitz, E. Chan, 2018, Cancer Chemotherapy and Pharmacology.

Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer

H. Hurwitz, D. Goldstein, H. Burris, 2015, Cancer Chemotherapy and Pharmacology.

Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials

C. Tournigand, C. Fuchs, R. Goldberg, 2020, Clinical trials.

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).

H. Hurwitz, J. Bendell, M. Pishvaian, 2015 .

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies

F. Kabbinavar, H. Hurwitz, L. Saltz, 2009, Journal of Cancer Research and Clinical Oncology.

Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007.

L. Shaw, J. Bertino, H. Hurwitz, 2007, Clinical colorectal cancer.

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer

H. Lenz, A. Grothey, H. Hurwitz, 2018, British Journal of Cancer.

Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy.

C. Willett, R. Clough, H. Hurwitz, 2007, International journal of radiation oncology, biology, physics.

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

C. Tournigand, D. Sargent, C. Bokemeyer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors

H. Hurwitz, J. Bendell, H. Pang, 2015, Cancer Chemotherapy and Pharmacology.

Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105

H. Hurwitz, H. Pang, C. Theuer, 2018, Molecular Cancer Therapeutics.

Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

K. Owzar, H. Hurwitz, A. Venook, 2016, Cancer medicine.

Disclosure between patients with gastrointestinal cancer and their spouses

H. Hurwitz, F. Keefe, L. Porter, 2005, Psycho-oncology.

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).

J. Reeves, B. Somer, H. Lenz, 2019, The oncologist.

Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?

G. Lyman, H. Hurwitz, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer

H. Hurwitz, S. Kaufmann, A. Adjei, 2011, Cancer investigation.

2136 : Adenocarcinoma of the Duodenum: A 30-Year Experience

C. Willett, H. Hurwitz, D. Tyler, 2006 .

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology

H. Hurwitz, G. Blobe, C. Theuer, 2014, Investigational New Drugs.

Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors

G. Shapiro, P. LoRusso, H. Hurwitz, 2011, Cancer Chemotherapy and Pharmacology.

APhase I-II Study of Docetaxel and Atrasentan inMenwith Castration-Resistant Metastatic Prostate Cancer

A. Armstrong, H. Hurwitz, D. George, 2008 .

Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis

J. Hecht, C. Bokemeyer, E. Van Cutsem, 2021, Therapeutic advances in medical oncology.

Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2010 .

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors

H. Hurwitz, T. George, Yining Du, 2018, OncoTargets and therapy.

Partner-assisted emotional disclosure for patients with GI cancer: 8-week follow-up and processes associated with change

Hong-Jin Kim, H. Hurwitz, D. Baucom, 2012, Supportive Care in Cancer.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

C. Tournigand, D. Sargent, R. Simes, 2018, Journal of the National Cancer Institute.

Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden.

Tony P. Smith, H. Hurwitz, M. Morse, 2016, Journal of gastrointestinal oncology.

Influence of prognostic groupings and treatment results in the management of unresectable hepatoma: experience with Cisplatinum-based chemoradiotherapy in 76 patients.

R. Abrams, H. Hurwitz, C. Enger, 1997, International journal of radiation oncology, biology, physics.

Multiagent Chemotherapy for Isolated Colorectal Liver Metastases: A Single-centered Retrospective Study

H. Hurwitz, J. Bendell, D. Niedzwiecki, 2008, Journal of Gastrointestinal Surgery.

Adjuvant Hepatic Arterial Chemotherapy Following Metastasectomy in Patients With Isolated Liver Metastases

H. Hurwitz, D. Tyler, M. Morse, 2003, Annals of surgery.

A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB

R. Schilsky, H. McLeod, R. Goldberg, 2007 .

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

Eileen M O'Reilly, Ghassan K Abou-Alfa, G. Abou-Alfa, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early evidence of tolerability and clinical activity from a phase I study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer.

H. Hurwitz, L. Rosen, C. Theuer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

A. Grothey, H. Hurwitz, M. Fakih, 2019, Annals of Oncology.

Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.

L. Grochow, K. Lillemoe, J. Cameron, 2000, International journal of radiation oncology, biology, physics.

Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients

R. Advani, H. Hurwitz, C. Verschraegen, 2008 .

Ambivalence over emotional expression in patients with gastrointestinal cancer and their caregivers: Associations with patient pain and quality of life

H. Hurwitz, I. Lipkus, F. Keefe, 2005, Pain.

Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers

J. Baselga, J. Tabernero, H. Hurwitz, 2007 .

Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?

C. Willett, H. Hurwitz, D. Tyler, 2012, Journal of surgical oncology.

A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.

H. Hurwitz, J. Bendell, G. Blobe, 2011, Anticancer research.

Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors.

H. Hurwitz, R. Riedel, J. Bendell, 2016, Journal of Clinical Oncology.

Phase III study of standard triweekly versus dose-dense biweekly capecitabine (C) + oxaliplatin (O) + bevacizumab (B) as first-line treatment for metastatic colorectal cancer (mCRC): XELOX-A-DVS (dense versus standard): Interim analysis.

H. Hurwitz, D. Spigel, E. Mitchell, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors

D. Potvin, J. Christensen, Keunchil Park, 2022, Targeted Oncology.

A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC).

G. Abou-Alfa, H. Hurwitz, N. S. Tchekmedyian, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2011, Journal of Clinical Oncology.

Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carcinoma of the Ampulla of Vater: Patterns of Failure after Resection and Possible Benefit of Adjuvant Radiotherapy

R. Clough, H. Hurwitz, D. Tyler, 2005 .

Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.

D. Sargent, M. Buyse, J. Hecht, 2014 .

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

L. Lipton, H. Hurwitz, L. Rosen, 2013, BMC Cancer.

Phase I dose-escalation study of the anti-VEGFR-2 recombinant human IgG1 MAb IMC-1121B administered every other week (q2w) or every 3 weeks (q3w) in patients (pts) with advanced cancers

H. Hurwitz, E. Rowinsky, E. Chiorean, 2007 .

HER2 testing in metastatic colorectal cancer: ready for prime time?

H. Hurwitz, 2016, Clinical advances in hematology & oncology : H&O.

Plasma protein markers in advanced or metastatic colorectal cancer patients receiving chemotherapy with bevacizumab or cetuximab: Results from CALGB 80405 (Alliance).

J. Meyerhardt, K. Owzar, H. Lenz, 2021, Clinical Cancer Research.

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

H. Hurwitz, J. Bendell, K. Lechner, 2019, The oncologist.

Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

Daniel J Sargent, Somnath Sarkar, D. Sargent, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer.

A. Grothey, H. Hurwitz, M. Fakih, 2018 .

Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC)

F. Kabbinavar, H. Hurwitz, E. Holmgren, 2005 .

Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

J. Reeves, B. Somer, H. Lenz, 2016 .

Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.

C. Tournigand, D. Sargent, J. Hecht, 2013 .

A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beam radiotherapy for treatment of locally advanced, unresectable, or recurrent rectal cancer.

G. Rosner, M. Dewhirst, T. Samulski, 2000, International journal of radiation oncology, biology, physics.

Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC).

J. Albanell, J. Tabernero, H. Hurwitz, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of erlotinib, bevacizumab, and external beam radiation therapy (RT) for patients with localized pancreatic carcinoma (PC).

C. Willett, H. Hurwitz, D. Tyler, 2011, Journal of Clinical Oncology.

Arterial thromboembolic events and patients with metastatic carcinoma treated with chemotherapy and bevacizumab (Journal of the National Cancer Institute (2007) 99 (1232-1239))

F. Kabbinavar, H. Hurwitz, H. Gerber, 2008 .

Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database.

Qian Shi, Daniel J. Sargent, Fang-Shu Ou, 2017 .

Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.

T. J. Mcmanus, H. Hurwitz, W. Petros, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).

Nikhil Uppal, Jason Clark, Philip J. Stella, 2014 .

Bevacizumab improves outcomes of patients with metastatic colorectal cancer (mCRC) treated with IFL with or without bevacizumab (BV) independent of baseline risk.

F. Kabbinavar, H. Hurwitz, A. Zurlo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer

R. Jain, Y. Boucher, E. Paulson, 2007, Nature Clinical Practice Oncology.

Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway.

J. Hainsworth, R. Bose, C. Swanton, 2017 .

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

G. Shapiro, H. Hurwitz, T. Busman, 2014, Investigational New Drugs.

Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer

J. Barrett, H. Hurwitz, P. Quirke, 2017, JAMA oncology.

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.

H. Hurwitz, J. Bendell, M. Morse, 2012, Journal of Clinical Oncology.

1049OSAFETY AND EFFICACY OF MPDL3280A (ANTI-PDL1) IN COMBINATION WITH BEVACIZUMAB (BEV) AND/OR CHEMOTHERAPY (CHEMO) IN PATIENTS (PTS) WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS.

H. Hurwitz, J. Bendell, M. Pishvaian, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).

K. Owzar, H. Lenz, H. Hurwitz, 2016 .

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The oncologist.

Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma.

C. Willett, R. Clough, H. Hurwitz, 2011, International journal of radiation oncology, biology, physics.

Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)

A. Grothey, H. Hurwitz, W. Novotny, 2004 .

Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.

H. Hurwitz, J. Favaro, W. Honeycutt, 2006, Clinical colorectal cancer.

Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).

Cristina Santos, H. Hurwitz, J. Bendell, 2017 .

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The oncologist.

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

Lindsay A. Renfro, Herbert I. Hurwitz, L. Diaz, 2017, Clinical Cancer Research.

Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate.

H. Hurwitz, C. Thomas, M. Kozloff, 1991, The Journal of rheumatology.

HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC)

J. Barrett, K. Owzar, H. Hurwitz, 2015 .

H. Hurwitz, C. Sweeney, E. Chiorean, 2015 .

Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients

A. Armstrong, H. Hurwitz, J. Bendell, 2007 .

Phase I studies

G. Shapiro, H. Hurwitz, M. Carducci, 2010 .

The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors

H. Hurwitz, Sunil Sharma, P. Jordaan, 2019, Cancer Chemotherapy and Pharmacology.

Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study.

J. Hainsworth, R. Bose, C. Swanton, 2016 .

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, The New England journal of medicine.

Clinical Cancer esearch cer Therapy : Clinical se I Safety , Pharmacokinetics , and Inhibition of Src R ivity Study of Saracatinib in Patients with Solid Tumors

I. Chirivella, J. Tabernero, P. Elvin, 2010 .

A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer

K. Blackwell, H. Hurwitz, P. Marcom, 2019, BMC Cancer.

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.

J. Berlin, H. Lenz, V. Giranda, 2014 .

Phase I Trial of Pazopanib in Patients with Advanced Cancer

E. Merkle, H. Hurwitz, A. Dowlati, 2009, Clinical Cancer Research.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, The New England journal of medicine.

Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.

O. Margalit, W. Harmsen, H. Lenz, 2022, European journal of cancer.

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The Oncologist.

D. Cella, F. Kabbinavar, H. Hurwitz, 2008, The Oncologist.

A phase I study of bevacizumab (BV) plus ABT-510 in patients with advanced solid tumors

H. Hurwitz, J. Bendell, M. Morse, 2007 .

Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)

Ivo D. Shterev, K. Owzar, H. Hurwitz, 2014, Clinical Cancer Research.

Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.

D. Sargent, M. Buyse, C. Fuchs, 2013 .

Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.

C. Willett, R. Clough, H. Hurwitz, 2009, International journal of radiation oncology, biology, physics.

The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors.

L. Lipton, H. Hurwitz, L. Rosen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

312 A Novel Assay for the Met Inhibitory Activity of MGCD265 in Plasma From Solid Tumor Patients in a Dose Escalating Phase I Study

G. Shapiro, H. Hurwitz, C. Maroun, 2012 .

Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.

C. Fuchs, R. Goldberg, H. Hurwitz, 2005, Clinical advances in hematology & oncology : H&O.

Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.

E. Van Cutsem, C. Punt, J. Tabernero, 2023, Journal of Clinical Oncology.

Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).

M. Hidalgo, H. Hurwitz, C. Verslype, 2017 .

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies

F. Kabbinavar, H. Hurwitz, L. Saltz, 2009, Journal of Cancer Research and Clinical Oncology.

Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

H. Hurwitz, R. Griffiths, T. Coffman, 2009, Hypertension.